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ARTICLE OPEN ACCESS
Impulse control disorders in Parkinson and RBD
A longitudinal study of severity
Fahd Baig, MRCP, PhD,*Mark J. Kelly, MBBch, BAO,*Michael A. Lawton, MPhil, Claudio Ruffmann,MRCP, PhD,
Michal Rolinski, MRCP, DPhil, Johannes C. Klein, MD, PhD, Thomas Barber, MRCP, Christine Lo, MRCP,







To describe the prevalence, natural history, and risk factors for impulse control behaviors
(ICBs) among people with Parkinson disease (PD), those with REM sleep behavior disorder
(RBD), and controls.
Methods
Participants with early PD (within 3.5 years of diagnosis), those with RBD, and controls were
clinically phenotyped and screened for ICBs longitudinally (with the Questionnaire for Im-
pulsivity in Parkinson’s Disease). ICB-positive individuals were invited for a semistructured
interview, repeated 1 year later. The severity of the ICB was assessed with the Parkinson’s
Impulse Control Scale. Multiple imputation and regression models were used to estimate ICB
prevalence and associations.
Results
Data from 921 cases of PD at baseline, 768 cases at 18 months, and 531 cases at 36 months were
included, with 21% to 25% screening positive for ICBs at each visit. Interviews of ICB screen–
positive individuals revealed that 10% met formal criteria for impulse control disorders (ICD),
while 33% had subsyndromal ICD (ICB symptoms without reaching the formal diagnostic
criteria for ICD). When these data were combined through the use of multiple imputation, the
prevalence of PD-ICB was estimated at 19.1% (95% confidence interval 10.1–28.2). On follow-
up, 24% of cases of subsyndromal ICD had developed full symptoms of an ICD. PD-ICD was
associated with dopamine agonist use, motor complications, and apathy but not PD-RBD. ICD
prevalence in the RBD group (1%) was similar to that in controls (0.7%).
Conclusions
ICBs occur in 19.1% of patients with early PD, many persisting or worsening over time. RBD is
not associated with increased ICD risk. Psychosocial drivers, including mood and support
networks, affect severity.
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Impulse control behaviors (ICBs) in Parkinson disease (PD) are
a range of behaviors linked by their reward-based, repetitive
natures (hereafter referred to collectively as ICBs including the
related behaviors). Impulse control disorders (ICDs) are defined
as behaviors with sufficient impact on social or occupational
function to meet “caseness” for disorder, while subsyndromal
ICDs comprise the remainder of the full spectrum of ICBs. Most
studies have taken a categorical rather than dimensional ap-
proach to the presence of ICBs despite the observation that these
behaviors are common, dimensional in nature, and variably as-
sociatedwith distress. To date, this has limited our understanding
of the risk factors for and natural history of ICBs. For instance, it
is still unclear whether the subsyndromal ICDs convert to full
ICDs, remit, or continue in their subsyndromal forms.
Prevalence estimates of PD-ICBs vary between 14% and
40%,1–6 with part of the variability due to the absence of gold-
standard semistructured interviews that conform to DSM-5
(or DSM-5 aligned) diagnostic criteria. In addition, a lack of
prospective studies limits our understanding of the course and
prognosis of PD-ICBs.
Certain risk factors have been identified, including dopami-
nergic medication, predominantly dopamine agonists (DAs),
along with demographic and disease-specific factors such as the
presence of motor complications. In addition, while the pres-
ence of REM sleep behavior disorder (RBD)may infer a higher
risk of developing PD-ICD,7,8 it is not known whether RBD
itself or whether a particular RBD-PD subtype confers an in-
crease risk.9
We aimed to address the following questions: What is the
distribution and severity of PD-ICBs, and how does this vary
over time? What is the expected prevalence of PD-ICBs? Fi-
nally, which clinical factors are associated with PD-ICBs?
Methods
Participants
This study was nested within the Oxford Parkinson’s Disease
Centre Discovery cohort, a large, multicenter, UK-based
prospective study of patients with early PD under longitudinal
follow-up. Full details of the protocol have been described
Glossary
CI = confidence interval; DA = dopamine agonist; DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th edition;
ICARUS = Impulse Control Disorders and the Association of Neuropsychiatric Symptoms, Cognition and Quality of Life in
Parkinson Disease; ICB = impulse control behavior; ICD = impulse control disorder; LEDD = levodopa equivalent daily dose;
MDS-UPDRS = Movement Disorder Society–revised Unified Parkinson’s Disease Rating Scale; PICS = Parkinson’s Impulse-
Control Scale; QUIP = Questionnaire for Impulse Control Disorders in Parkinson’s Disease; QUIP-S = QUIP Short Form;
RBD = REM sleep behavior disorder.
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elsewhere.9–11 In brief, patients with PD diagnosed within
3.5 years were recruited to the cohort between September
2010 and September 2014. Cases were eligible for inclusion if
they met the UK PD Brain Bank criteria for diagnosis12 re-
gardless of their age at onset, family history, or cognitive
status. Follow-up visits were every 18 months, at which point
the diagnosis was reviewed by a specialist in movement
disorders.
The control population, recruited from spouses and general
public volunteers in the same region, were assessed to ensure
that they did not have PD or a first-degree relative with PD.
The RBD group comprised participants with a diagnosis made
by clinical assessment and polysomnography according to
standard International Classification of Sleep Disorders-II
criteria.13 Participants were excluded from this group if their
symptoms were judged to be due to medications or associated
with another neurologic condition.
At each visit, clinical assessments were performed with
validated tools to assess a broad range of motor and non-
motor symptoms. These assessments included cognition
(Montreal Cognitive Assessment); personality (Big Five
Inventory); orthostatic hypotension (lying and then
3-minute standing blood pressure); hyposmia (the 16-stick
Sniffin’ Sticks odor identification test); RBD (Rapid Eye
Movement Sleep Behavior Disorder Screening Question-
naire); dexterity (Purdue Pegboard Test); and the Move-
ment Disorder Society–revised Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS). During the study period, the
more commonly used Hospital Anxiety and Depression
Scale replaced the Leeds Anxiety and Depression Scale for
mood assessment. Hospital Anxiety and Depression Scale
scores were calculated with the Leeds Anxiety and De-
pression Scale when missing with standard equipercentile
methods, which we have published previously, for consis-
tency and ease of interpretation.14,15
Assessment of ICBs
At baseline and then every 18 months, all participants com-
pleted the Questionnaire for Impulse Control Disorders in
Parkinson’s Disease (QUIP) Short Form (QUIP-S16) to
identify participants with possible PD-ICD. All participants
screening positive on their most recent QUIP assessment
were invited to an interview between September 2015 and
June 2016. Each participant was invited to participate in
a semistructured interview either by telephone or in clinic,
depending on patient preference.
The Parkinson’s Impulse-Control Scale (PICS17) is a clini-
cian-rated scale based on a semistructured interview used to
measure both the frequency and impact of a range of ICBs and
to provide an index of severity. Seven ICBs are included in the
PICS; gambling, shopping, eating, hypersexuality, simple
(punding) and complex (hobbyism) repetitive behaviors, and
compulsive overuse of medication (dopamine dysregulation
syndrome), with or without off-period dysphoria. It has been
validated in PD, has high interrater reliability, and has been
proven sensitive to change.17 For each ICB, structured
questions specific to the behavior are used to collect in-
formation on the intensity of the behavior (frequency and
scale of behavior, score 1–4) and its riskiness and impact on
the individual and others (e.g., financial or social effects, score
1–3). Higher scores denote greater severity. Intensity and
impact scores are multiplied to give a single severity score with
a total severity indicated by the sum of the 7 ICBs.
Two clinicians with an interest in movement disorders per-
formed the interviews after training from a neuropsychiatrist
with a special interest in these disorders (D.O.), recording both
quantitative and qualitative information. Interviewers discussed
all cases potentially symptomatic with an ICB with both the
other interviewer and the neuropsychiatrist to confirm the di-
agnosis. To meet criteria for a PD-ICB, behaviors needed to be
de novo in nature or judged as an exacerbation of preexisting
behaviors after administration of dopaminergic medication.We
use the term subsyndromal ICD to describe cases with symp-
toms of ICB that were not severe enough to meet the di-
agnostic criteria for PD-ICD. ICD (in cases without PD) or
PD-ICD was diagnosed with DSM-518 or published criteria for
PD-ICD.19–22
If a patient was found to have PD-ICD, then the patient’s
physician, specialist nurse, and family practice doctor were
informed with the patient’s permission. In addition, an age-
and sex-matched sample of participants who screened nega-
tive for ICB were also invited for the more in-depth interview
so that we could ascertain the sensitivity and negative pre-
dictive value of the screening methodology.
All participants found to have ICB after the in-depth interview
were invited to an identical follow-up interview 12 to 18
months later.
Statistical analysis
We estimated the prevalence of PD-ICB in 2 ways. First, we
assumed that the prevalence of PD-ICBs was the same in the
participants who participated in the in-depth questionnaire
and those who were invited but were not interviewed
(nonresponders). Then we used multiple imputation with
25 imputed datasets to account for the missing data on
caseness for the nonresponders. This allowed us to examine
for any potential bias due to nonresponse to the interview
invitation.
We then used logistic regression to determine which clinical
variables were associated with PD-ICBs. Variables with crude
associations giving a value of p < 0.2 were carried over to
calculate adjusted associations in a multivariable model. We
then used backward stepwise selection to include all variables
associated with values of p < 0.05 in the final model. The
clinical data collected at the time of interview and measure-
ments from the corresponding study visit were used in the
analysis of the in-depth interview.
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Data availability
Applications for deidentified data can be made to the Ox-
ford Parkinson’s Disease Centre (opdc.ox.ac.uk/external-
collaborations).
Ethics approval and consent
We obtained informed consent from each participant.
Ethics approval for this study was granted by the Berk-
shire Ethics Committee, South Central, National
Research Ethics Service (United Kingdom, reference
No. 10/H0505/71).
Results
By January 2018, 932 cases of PD had been recruited; 11
(1.2%) had missing data and were excluded. Follow-up
data were available for 768 of 932 (82%) cases at 18
months and 531 of 932 (57%) at 36 months. Attrition was
due to a combination of withdrawal from the study, death,
or participants still awaiting follow-up. Study participants
who had screened positive for ICD at their most recent
visit on September 29, 2015, were invited to the in-depth
interview. Figure 1 provides a flowchart of the selection
process, and table 1 gives the demographics of included
participants. Full baseline features have been published
previously.9
Distribution of ICBs over time with
a screening tool
According to the QUIP-S screening tool, 21% (195 of 921,
95% confidence interval [CI] 18.6–24.0) of the PD group
reported symptoms of ICB at baseline. On follow-up, 24%
(184 of 768, 95% CI 21.0–27.1) screened positive at
18 months, and 25% (133 of 531, 95% CI 21.4–29.0)
screened positive at 36 months. The number of participants
Figure 1 Participant selection and results from in-depth interviews
This figure illustrates the selection
process for in-depth interviews with
theQuestionnaire for Impulse Control
Disorders in Parkinson’s Disease
(QUIP) screening tool and demon-
strates the changes in impulse control
behavior (ICB) category between the
first and second interviews. Partic-
ipants with subsyndromal impulse
control disorder (ICD) at the first in-
terview are separated into 2 catego-
ries: those who had previously met
the criteria for PD-ICD (retrospec-
tively) and those whose symptoms
had always been subsyndromal ICD.
PD = Parkinson disease.
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with PD reporting >1 PD-ICB also remained stable over
the follow-up visits. At baseline, this was 8.3% (76 of 921,
95% CI 6.6–10.2); at 18 months, 8.3% (64 of 768, 95% CI
6.5–10.5); and 36 months, 9.6% (51 of 531, 95% CI
7.2–12.4).
The distribution of PD-ICB domains was largely un-
changed over the 3-year follow-up period (figure 2). Hob-
byism was the most common PD-ICB domain, with
gambling and walkabout the least common. Compulsive
eating, shopping, and hypersexuality were reported at
similar frequencies.
Distribution and severity of ICB with an in-
depth interview
There were no significant differences in the demographics
of the cases who responded and those who did not respond
to the invitation to the in-depth interview. Table 2 summa-
rizes the results of the in-depth interview, with 10% (9 of 88)
meeting the criteria for PD-ICD and 33% (29 of 88) consis-
tent with subsyndromal ICD.
Two participants had symptoms of ICB that predated their
diagnosis of PD and had remained unchanged during adult-
hood; thus, they were not considered to have PD-ICB. The
Table 1 Baseline demographics of included participants with PD
Cases of PD: screened
negative for ICBs (n = 726)
Cases of PD: screened
positive for ICBs (n = 195)
Age, mean, range (SD), y 68.5, 39–90 (9.1) 63.0, 32–84 (9.6)
Female, n (%)a 259 (35.7) 63 (32.3)
Nonwhite, n (%) 12 (1.7) 8 (4.1)
First-degree relatives with PD, n (%) 103 (14.3) 39 (20.0)
Disease duration from PD diagnosis, mean (interquartile range), y 0.9 (0.4–1.8) 1.5 (0.6–2.4)
Disease duration from symptom onset, median (interquartile range), y 2.4 (1.5–3.5) 2.9 (2.0–4.0)
Age at PD diagnosis, mean, range (SD), y 67.3, 38–90 (9.1) 61.5, 31–83 (9.7)
MDS-UPDRS part III score, mean (SD) 26.7 (11.0) 25.9 (9.8)
Hoehn and Yahr stage, n (%)
1 168 (23.2) 42 (21.5)
2 502 (69.4) 143 (73.3)
3 53 (7.3) 10 (5.1)
Untreated PD, n (%) 101 (13.9) 11 (5.6)
LEDD (treated patients only), mean (SD) 311 (188) 367 (216)
Treated participants on the following medications, n (%)
Levodopa 406 (65.0) 106 (57.6)
DA 178 (28.5) 98 (53.3)
MAOB-I 164 (26.2) 62 (33.7)
Cognition (Montreal Cognitive Assessment score, normal cognition >23,
range 0–30), mean, median (interquartile range)
24.9, 25 (23–27) 25.3, 26 (24–28)
Depression (Hospital Anxiety and Depression Scale score, range 0–21),b
mean, median (interquartile range)
4.0, 3 (1–6) 5.6, 5 (3–8)
Meets screening criteria for depression (Hospital Anxiety and Depression
Scale score ≥8),b n (%)
104 (14.6) 55 (28.1)
Anxiety (Hospital Anxiety and Depression Scale score, range 0–21),b
mean, median (interquartile range)
4.1, 3 (1–6) 6.2, 5 (3–9)
Meets screening criteria for anxiety (Hospital Anxiety and Depression
Scale score ≥8),b n (%)
120 (16.8) 67 (33.5)
Abbreviations: DA = dopamine agonist; LEDD = levodopa equivalent daily dosage; MAOB-I = monoamine oxidase-B inhibitor; MDS-UPDRS III = Movement
Disorder Society–revised Unified Parkinson’s Disease Rating Scale; PD = Parkinson disease.
a All participants included in this study identified as either male or female.
b Hospital Anxiety andDepression Scale equivalent scores were calculated using equipercentile equating from the Leeds Anxiety andDepression Scale in 81%
of cases.
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remaining 48 participants did not have symptoms of PD-ICB.
To check the negative predictive value of the screening
method, an age- and sex-matched sample of 89 participants
with PD who screened negative on the QUIP were invited to
interview, of whom 48% (43 of 89) took part. None of those
interviewed had PD-ICD, but 3 had symptoms of sub-
syndromal PD-ICD (negative predictive value 93%).
A similar proportion of the control group (21%, 61 of 295) and
a slightly higher proportion of the participants with RBD (34%,
35 of 102) screened positive for ICB. Of these, 52% (32 of 61)
of the control group and 49% (17 of 35) of the RBD group
participated in the in-depth interview. In the control group, 2
(0.7% of total) participants met the criteria for a compulsive
eating disorder, one of whom also had a diagnosis of attention-
deficit/hyperactivity disorder. In the RBD group, 1 participant
(1% of total) met the criteria for binge eating disorder, which
had been long-standing without any noticeable association of
severity since the diagnosis. No other ICDs were determined.
Binge eating disorder was the most common domain in the in-
depth interview, followed by hypersexuality, hobbyism, and
compulsive shopping. While the QUIP seemed to overestimate
hobbyism, the domains were otherwise similar in proportion.
Subsyndromal PD-ICDs were more common than ICDs.
There were no clear differences in the characteristics of the 2
groups. More than half the cases with either subsyndromal
ICD or ICD had symptoms in >1 domain. The total levodopa
equivalent dailydose (LEDD) and types of dopaminergic
medication used were broadly similar in each group. While
binge eating was the most common finding in subysndromal
ICD (59%, 95% CI 39–76), hypersexuality was the most
common PD-ICD (66%, 95% CI 30–93). However, the small
absolute numbers make comparisons between groups difficult.
Severity scores were higher in the PD-ICD group, as would be
expected. This reflects not only the increased severity of each
individual domain but also the additive nature of multiple
domains involved in PD-ICD.
However, it is noteworthy that 28% (8 of 29) of cases with
subsyndromal ICD had a moderate severity score in their
worst affected domain, indicating a notable effect on their
well-being in excess of what would be expected in the sub-
syndromal category. Each of these cases had symptoms that
had until recently been consistent with PD-ICD but, at the
time of interview, had improved to the extent that they no
longer fulfilled the full criteria. Despite the improvement in
the intensity of the symptoms, the impact of the more severe
symptoms was ongoing (e.g., weight gain due to compulsive
eating and the social ramifications of hypersexuality). The
detrimental effects of subsyndromal ICD in itself, though,
were important to the individual, with almost 1 in 3 cases
reporting family difficulties as a result of this behavior.
Symptoms of PD-ICD tended to occur relatively soon after
the patients started dopaminergic medication, while there was
a greater range in time to symptom onset in the subsyndromal
ICD group, although this did not meet the threshold for
significance on formal testing.
We recorded a summary of each interview to allow post hoc
qualitative data analysis, which revealed some recurring
Figure 2 Categories of ICB found on screening at baseline and follow-up
This figure demonstrates the percentage of cases of Parkinson disease (PD) screening positive for each impulse control behavior (ICB) at each of the first 3
visits, each ≈18 months apart. If an individual had screened positive for more >1 PD-ICB, each positive result has been included.
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themes. An observed trend was that at least 13 in the sub-
syndromal ICD group described that their change in behavior
was consistent with an exaggeration of long-standing
behaviors. The most common example was binge eating dis-
order; 10 of 17 cases described that they had a tendency to
binge eat before being diagnosed with PD, often in association
Table 2 Demographics and interview results of participants with PD with ICBs on in-depth interview
ICD (n = 9)
Subsyndromal
ICD (n = 29)
p Value, ICD vs
subsyndromal ICD
Female, n (%)a 3 (33) 12 (41) 0.67e
Age at interview, mean (SD), y 61.9 (7.5) 65.4 (7.9) 0.25f
Age at diagnosis, mean (SD), y 56.3 (7.9) 60.2 (7.5) 0.19f
Disease duration from diagnosis, mean (SD), y 5.6 (1.6) 5.2 (1.7) 0.60g
No. of ICB domains affected, n (%) 0.36g
1 4 (44) 14 (48)
>1 2 (22) 12 (41)
>2 3 (33) 3 (11)
Individual domains affected (either ICB or ICD), n (%)
Binge eating 4 (44) 17 (59)
Pathologic gambling 1 (11) 0
Hypersexuality 6 (67) 10 (34)
Compulsive shopping 4 (44) 8 (28)
Punding 1 (11) 2 (7)
Hobbyism 2 (22) 9 (31)
Dopamine dysregulation syndrome 4 (44) 1 (3)
LEDD, median (interquartile range), mgb 675 (575–850) 620 (500–750) 0.99f
Current medication use, n (%)
Monoamine oxidase inhibitor 1 (11) 7 (24%
Levodopa 8 (89) 26 (90)
Dopamine agonist 7 (78) 22 (76)
Both levodopa and dopamine agonist 6 (66) 19 (66)
Severity of ICB or ICD, n (%)c
Mild 0 21 (72)
Moderate 6 (67) 8 (28)
Severe 3 (33) 0
Severity of ICB or ICD, cumulative score, median
(interquartile range)d
4 (2–5) 10 (6–20)
Time from medication change to onset of first ICD, median
(interquartile range), mo
6 (3–12) 6 (2–30) 0.76g
Impact on relationships, n (%) 2 (22) Marital separations,
3 (33) marital difficulties
9 (31) Reported
family difficulties
Abbreviations: ICB = impulse control behavior; ICD = impulse control disorder; LEDD = levodopa equivalent daily dose; PD = Parkinson disease.
a All participants included in this study identified as either male or female.
b All patients were taking dopaminergic medication.
c Highest severity score is included if the individual had >1 ICB. Severity scores were categorized into mild (1–3), moderate (4–6), or severe (7–12).
d Sum of severity scores including all domains affected.
e Chi-square test.
f Student t test.
g Mann-Whitney U test.
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with stress. This contrasted with the participants with full ICD,
of whom only 2 described similar symptoms before PD onset
and would describe their symptoms as new or out of character.
Follow-up in-depth interviews of cases of PD
with ICB
At follow-up, 74% (28 of 38) of the cases of PD with ICB were
interviewed again after a minimum of 12 months (median
follow-up 15.6 months). The changes in ICB category between
the first and second interviews are illustrated in figure 1. Cases
maintained their ICDor subsyndromal ICD status, improved to
asymptomatic or subsyndromal ICD, or progressed to PD-ICD
from subsyndromal status. Those in the last category who had
been in remission are considered to have relapsed into PD-ICD.
Proportionally, symptoms of hypersexuality and dopamine dys-
regulation syndrome seemed to improve between the 2 inter-
views, while punding seemed to become more common (figure
3). Fourteen participants (50%) experienced an improvement in
the severity score of their most severe ICB; 6 (21%) remained
stable; and 8 (29%) experienced a worsening in this score.
Only 1 participant (of the 23 taking DAs) had withdrawn the
DA completely in the interval between first and second inter-
views. No participants were newly started on DA. Four cases
had stopped their DA recently before the first interview. Of the
5 subsyndromal ICD cases who had ceased taking a DA, 4
experienced a reduction in symptom severity between the first
and second interviews, while 1 case experienced an increase.
The average LEDD at the first interview among participants
with ICB was 666 (SD 344) mg and at the second interview
was 826 (SD 317) mg. The mean LEDD of DAs only in
participants with subsyndromal ICD and full ICD was 280
(SD 128)mg at the first interview and 331 (SD 212)mg at the
second interview. Changes in LEDD were associated with
both increases and decreases in ICB severity. There was no
significant relationship between change in LEDD or DA-
LEDD and change in ICB severity.
Qualitative data revealed that external factors were reported by
participants to directly influence the severity of ICB symptoms.
For example, 1 participant described recovering from a pro-
longed period of low mood (also after a bereavement), and this
recovery was accompanied by improvement in her over-
spending and hypersexual behaviors. Another reported social
isolation at the first interview but thereafter had joined several
new community groups and expanded her social circle, leading
(in her opinion) to resolution of her overspending behavior.
Severity scores could also vary because of changes in impact of
the symptoms, while the intensity of the behavior remained
the same. Similarly, the impact of a behavior that remained
stable in terms of intensity could become more troublesome
over time. An example is an increase in appetite, which led to
weight gain over time. Conversely, some participants reported
that while the urges for their behaviors may still have been
present, they and their families had developed a range of
coping strategies (including measures like financial control)
so that they minimized the effects of the impact.
Prevalenceof PD-ICBandassociated symptoms
The estimated prevalence of PD-ICB (including the full spectrum
of severity), assuming the same proportion in those who did not
have an in-depth interview and those who did, was 14.5% (95%
CI 12.4–16.9). The use of multiple imputation gave a slightly
higher estimate of 19.1% (95% CI 10.1–28.2), suggesting that
nonresponders were slightly more likely to have ICBs.
Figure 3 Categories of ICB at baseline and follow-up interview
Percentage frequency of impulse control behavior (ICB) domains in the in-depth first interview (n = 38) and follow-up interview (n = 28) (several participants
exhibited >1 ICB). DDS = dopamine dysregulation syndrome; ICD = impulse control disorder.
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Table 3 Crude and adjusted odds ratios for predictors of ICB using multiple imputation





Age at PD diagnosis 0.96 (0.92–0.99) 0.02
Female sex 1.51 (0.80–2.86) 0.21
BFI-44a
Extraversion 0.99 (0.94–1.04) 0.76
Agreeableness 1.00 (0.95–1.06) 0.90
Conscientiousness 0.99 (0.94–1.04) 0.65
Neuroticism 1.02 (0.97–1.07) 0.40
Openness 1.01 (0.97–1.05) 0.62
Vascular diseaseb 0.76 (0.42–1.36) 0.35
Alcohol consumption 0.47
1–14 vs 0 units/wk 0.88 (0.46–1.69)
≥15 vs 0 units/wk 0.55 (0.20–1.54)
SES variables sum scorec 0.31
1 vs 0 3.34 (0.68–16.32)
2 vs 0 3.44 (0.66–17.89)
3 vs 0 4.86 (1.07–22.18)
4 vs 0 (best SES) 4.83 (0.95–24.48)
Disease duration from diagnosis 1.22 (0.99–1.51) 0.07
LEDD (per 100 mg) 1.19 (1.03–1.37) 0.02
Levodopa use 0.71 (0.25–2.04) 0.52
DA use 3.77 (1.65–8.64) 0.002 4.38 (1.70–11.3) 0.003
Both levodopa and dopamine agonist use 3.08 (1.59–5.98) <0.001
MDS-UPDRS part III (per unit) 1.02 (0.99–1.05) 0.18
MDS-UPDRS part IV (per unit) 1.23 (1.07–1.40) 0.003 1.24 (1.05–1.48) 0.013
MDS-UPDRS motor phenotype (PIGDd vs not PIGD) 2.09 (1.05–4.15) 0.035
Purdue Pegboard Test (poor performance on the assembly task,
<20th centile)
1.03 (0.98–1.08) 0.30
Montreal Cognitive Assessment 0.31
MCI (21–22) vs normal (>23) 0.49 (0.19–1.25)
Dementia (<21) vs normal 0.73 (0.30–1.76)
Hospital Anxiety and Depression Scalee
Depression (score ≥8) 1.67 (0.83–3.35) 0.15
Anxiety (score ≥8) 2.19 (1.05–4.55) 0.04
Rapid Eye Movement Sleep Behavior Disorder Screening
Questionnaire (score >5)
1.45 (0.81–2.62) 0.21
Hyposmiaf 0.84 (0.38–1.86) 0.66
Orthostatic hypotensiong 0.46 (0.18–1.21) 0.12
MDS-UPDRS hallucinations (score ≥1) 4.33 (1.69–11.13) 0.003
Continued
Neurology.org/N Neurology | Volume 93, Number 7 | August 13, 2019 e9
The association of clinical symptoms with PD-ICB is shown
in table 3. DA use, severity of motor complications (MDS-
UPDRS IV score), and apathy were associated with PD-ICB
in the final model. The area under the curve for the final
model was 0.75 (95% CI 0.65–0.84).
Discussion
This is the first study to perform an in-depth semistructured
interview assessing the full range of ICB severity in a dimen-
sional and longitudinal manner. It therefore provides a more
granular, clinically relevant understanding of the course and
progression of symptoms compared with previous categorical
approaches to ICD presence. ICBs are common in the early
stages of PD (19.1% prevalence), with a larger proportion of this
population having symptoms of subsyndromal ICD without
meeting the established criteria for a disorder. In addition to DA
use, motor fluctuations and apathy are clinical predictors of ICB.
RBD, in the absence of PD or another neurodegenerative dis-
order, is not in itself associated with a greater risk of ICD.
Despite notification of the patient and the care teams, most of
the participants with these symptoms continued to be symp-
tomatic a year later, with a proportion of those with sub-
syndromal ICD going on to develop the more severe disorder.
Prevalence of ICBs
The results of the QUIP in this cohort (21%–25% screening
positive across 3 years) were less than those reported in the
Impulse Control Disorders and the Association of Neuro-
psychiatric Symptoms, Cognition and Quality of Life in
Parkinson Disease (ICARUS) study28 (a similarly large ob-
servational study), which reported a prevalence of 32% to 35%
of the cohort screening positive for PD-ICB, which remained
stable across 2 years. In contrast, a recently published longi-
tudinal study29 (with a younger cohort [mean age 62 years])
found a prevalence rate of 19.7% at baseline, which increased
to 32.8% after 5 years. Factors associated with increased
prevalence in that cohort included disease duration and dose
of DA used. These differences may be explained by the
younger sample and much higher proportion on DAs at
baseline compared to this cohort (74% vs 30%), thus having
a higher likelihood of developing ICB.
The in-depth PICS interview allows greater accuracy in de-
lineating subdomains compared to the QUIP screening ques-
tionnaire. Pathologic gambling was present in only 1 participant
in the in-depth interview, which may reflect a particular diffi-
culty in engaging with this group or greater responsivity to
medication alteration. The authors noted that during the in-
depth interview many of the patients with hobbyism reported
technology overuse as a major symptom, including smartphone
games and searching the internet. These device applications are
designed to encourage repeated use, so this may be particularly
problematic for those vulnerable to ICBs.30
Severity of ICBs
Relationship difficulties, including marital separation, are
common in moderate to severe PD-ICD and can be associ-
ated with subsyndromal behaviors. The overlap of moderate
symptom severity between both the subsyndromal ICD and
the full ICD group highlights the importance of recognizing
the full spectrum of these disorders and how the impact of the
behaviors can have a lasting detrimental effect on an indi-
vidual’s quality of life despite apparent improvement in the
symptoms. It also highlights the need for research in this
larger group of patients with PD-ICB.
In the follow-up interview, there was significant variation in
both the impact and intensity of PD-ICB, and thus the se-
verity, within a relatively short time frame. Many even
changed category between ICD, subsyndromal ICD, and
asymptomatic. This variation was not due to changes in DA
use or medication dose and contrasts with large prevalence
Table 3 Crude and adjusted odds ratios for predictors of ICB using multiple imputation (continued)





MDS-UPDRS apathy (score ≥1) 2.44 (1.30–4.56) 0.005 2.71 (1.34–5.52) 0.006
MDS-UPDRS fatigue (score ≥1) 1.08 (0.46–2.51) 0.86
MDS-UPDRS pain (score ≥1) 0.79 (0.36–1.70) 0.54
Abbreviations: BFI = Big Five Inventory; DA = dopamine agonist; ICB = impulse control behavior; CI = confidence interval; LEDD = levodopa equivalent daily
dose; MDS-UPDRS = Movement Disorder Society–revised Unified Parkinson’s Disease Rating Scale; OR = odds ratio; PD = Parkinson disease; PIGD = postural
instability and gait disorder; SES = socioeconomic status
a Personality was assessed with the BFI-44. This is a self-rated questionnaire that uses a 5-point scale to rate 44 short phrases of character to evaluate the 5-
factor model of personality: extraversion, neuroticism, agreeableness, openness, and conscientiousness.23,24
b Vascular risk factors includes presence of angina, heart failure, stroke or TIA, heart attack, diabetes mellitus, hypercholesterolemia, and hypertension.
c SES score includes 1 point for each of the following: extended formal education (>13 years), car ownership (>1 car in the household), property size (>3
bedrooms in house), and employment role (supervisory or professional role).
d PIGD.25
e Hospital Anxiety and Depression Scale scores were calculated using equipercentile equated from the Leeds Anxiety and Depression Scale in 23% of cases.
f Sniffin’ Sticks odor identification test dichotomized at the 15th percentile according to normal values for age and sex.26
g Blood pressure was measured after the patient lay flat for 3 minutes and then again after the patient stood upright for 2 minutes. A systolic drop of blood
pressure ≥20 mm Hg or a diastolic drop ≥10 mm Hg was deemed positive.27
h For those variables with a crude p < 0.2, backward stepwise selection was performed, with an entry value of p < 0.05 for the final model.
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studies that found a positive relationship between PD-ICD
and total LEDD.4,31 Further studies designed to examine this
relationship have found an association with total DA dose.29,32
However, these studies used categorical outcomes that may
not necessarily have reflected the dimensional approach of the
semistructured interview.
In addition, the in-depth interviews allowed preliminary ex-
ploration of possible subtypes of PD-ICB. Many of the
patients with subsyndromal PD-ICD described that their
symptoms were preexisting behaviors (before medication
initiation) that had worsened, e.g., worsening of symptoms in
those with a tendency to heavier internet use or a proclivity to
comfort eating after titration of their PD medication. In
contrast, cases with syndromal PD-ICD often described
a relatively rapid onset of a behavioral change that the par-
ticipants described as new or out of character (e.g., a change in
sexual orientation or a novel gambling habit) after the initi-
ation of a DA. The first subtype may experience a gradual
worsening of preexisting ICB symptoms in a dose-responsive
fashion to dopaminergic medication, while a different group
may have a predisposition to a more rapid and catastrophic
PD-ICD, leading to conflicting results.
Some participants met with their physician, who felt that
withdrawal in the context of only mild symptoms, on balance,
was not necessary. The common difficulties of agonist with-
drawal (e.g., DA withdrawal syndrome33) were described by
some patients during the follow-up interview. Some managed
only a modest reduction in DA or a switch to a weaker agonist
preparation. This highlights the need for other forms of in-
tervention in PD-ICB such as cognitive behavioral therapy to
allow a more holistic approach.34
Medication was not the only factor to influence the severity of
PD-ICB. The qualitative data recorded suggested an impor-
tant role for internal factors (mood and coping mechanisms)
and external factors (major life events and social support
networks), consistent with the literature.35 Addressing these
factors may help manage the full spectrum of PD-ICB, pre-
venting the transition from subsyndromal to ICD, and may
even allow more modest reductions in medications and thus
better symptom control. PD-ICD increases caregiver burden
over PD alone,36 and better social functioning increases the
chances of improvement in severity.37
The incidence of depression is higher among participants with
PD with ICD than those without.28,38 A study39 that used
objective quantitative measures of psychological factors such
as mood, anxiety, and a lack of healthy coping strategies found
that these factors were significant predictors of PD-ICD in-
cidence. The causal relationship between ICB and such fac-
tors is difficult to determine, but a conceptual model40
proposes that the effect of underlying psychosocial stressors is
multiplied by the effect of DAs to cause PD-ICD. This is
supported by evidence that psychotherapeutic strategies such
as cognitive behavioral therapy35 and support groups41 are
effective in reducing the severity of both mood disorders
(such as depression and anxiety) and ICD itself.
Factors associated with ICBs
While the precise etiology of PD-ICB remains unclear, the
ability to predict individuals who are at risk for developing these
behaviors, and thus avoiding precipitating medication, would
have immediate clinical utility. Consistent with previous stud-
ies, the use of dopaminergic medication, particularly DAs, was
most strongly associated with the presence of ICBs. The se-
verity of motor complications was also independently associ-
ated with ICBs. Thesemotor associationsmay at least in part be
explained by motor progression of advancing PD or an in-
creasing LEDD, although these were not independently asso-
ciated with PD-ICB. Motor symptoms, as measured by the
MDS-UPDRS III, have been inconsistently associated with PD-
ICB, but this has been largely in studies using screening tools
for diagnosis as opposed to a formal interview. The ALTHEA
study42 similarly found a strong association between dyskinesia
and PD-ICB, although the reported rates were higher in that
study due to the use of a screening tool for diagnosis.
Similar to the ICARUS study, apathy was associated with PD-
ICB.28 The replication of apathy being associated with the
presence of PD-ICB is intriguing in that it is linked to reward
insensitivity, which is modulated by dopaminergic medica-
tion.43 Apathy is increasingly recognized in PD, and it may be
that disruption of these same pathways between the prefrontal
cortex and basal ganglia, which are integral to reward sensi-
tivity, causes a susceptibility to ICD. Mood disorders such as
anxiety and depression, which have been associated with PD-
ICB, correlate strongly with apathy, so previous studies may
have associated these potential confounding variables. The
alternative, given that these patients seem to have a high drive
and motivation for reward-based activities, is that this obser-
vation may in fact represent a “pseudo-apathy” in which, akin
to a substance user, patients lose interest in non–substance
use–related reward activities.
In contrast to previous studies, we did not identify age, sex,
cognition, sleep disorders, and marital status as risk factors
in the PD group. PD-RBD was identified as an independent
risk factor in a large cross-sectional study.8 This finding
was then replicated in cohorts with both clinically44 and
polysomnography7-diagnosed PD-RBD. Further studies with
smaller sample sizes,45–47 aiming to specifically address this
question, have failed to show this association. This large study
adds robust evidence for the lack of association between PD-
RBD and PD-ICD.
ICBs in RBD
Despite many participants with RBD and controls screening
positive on theQUIP, only 1% of the total of each groupmet the
criteria for ICD, indicating that RBD in itself is not a risk factor.
The increased reporting of potentially abnormal behaviors on
the self-completed screening questionnaire (QUIP) by the RBD
group compared to controls may reflect a reporting bias. Patients
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with RBD are aware that they are at risk of developing a neuro-
degenerative disease such as PD andmay therefore overestimate
their symptoms. Although the mechanisms for ICD are not yet
fully understood, the primary driver is thought be dopaminergic
medication, to which the RBD group was not exposed. In ad-
dition, studies investigating the pathophysiology of ICD impli-
cate abnormal signaling of dopaminergic projections into the
striatum, orbitofrontal cortex, anterior cingulate, and anterior
insula, areas that are not implicated in the pathology of RBD.48,49
Major strengths of our study include the following: one of the
largest prospective studies to examine PD-ICB; the adoption
of a dimensional compared with the more categorical ap-
proach to this range of disorder; the inclusion of patients with
incident cognitive impairment, because their exclusion may
bias the findings to less aggressive PD subtypes (thus, this
unselected cohort is highly representative of early PD); and
the use of recognized diagnostic criteria based on an in-depth
interview that allows greater accuracy of diagnosis compared
to screening questionnaires. Study limitations include the
≈50% participation rates for the in-depth interview, although
the literature indicates that patients with PD-ICB are in fact
significantly more likely to respond to a follow-up survey than
patients with PD without ICBs.6 The additional use of mul-
tiple imputation mitigates against potential bias in response
rate, in contrast to the many ICD prevalence studies that
merely reported the crude observed prevalence. A second
limitation is that there may still be residual confounding dif-
ferences in determining risk factors even though we have used
a multivariable model. Finally, the relatively small absolute
number of patients with ICBs for follow-up may prove a lim-
itation. However, the in-depth interview allows a significant
amount of detail to be collated on each participant.
This study highlights the importance and potential impact
across the full spectrum of severity of PD-ICB symptoms. Long-
term management of these symptoms is challenging because
symptoms persist and may even worsen, highlighting the need
for holistic care, including nonpharmacologic therapies.
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